Bimatoprost in Diabetic Patients: Glaucoma Safety & Macular Edema Risk
Bimatoprost 0.03% ophthalmic solution is approved for glaucoma/ocular hypertension in diabetic patients. However, diabetics have a higher baseline risk of macular edema, especially post-cataract surgery. Clinical trials show bimatoprost does not significantly increase this risk, but monitoring is prudent:
- Baseline OCT macula before starting.
- Periodic OCT if diabetic retinopathy or prior cataract surgery.
- Discontinue if macular edema develops/worsens.
Overall, benefit of IOP lowering outweighs risk in most diabetic glaucoma patients.
Diabetes - Related Articles
- Understanding and Managing Hyperglycemia: Causes & Treatment
- Low Testosterone & Type 2 Diabetes: Exploring the Connection & Treatment
- FreeStyle Flash Meter Error Codes: Troubleshooting & Solutions
- Managing Diabetes Through Diet: A Comprehensive Guide
- Understanding Insulin Injection Side Effects: What You Need to Know
- Safe & Effective Exercises for Diabetes Management | Mayo Clinic Insights
- Natural Blood Sugar Control: Alternatives to Medication
